Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 20,342 shares, a decrease of 23.0% from the November 30th total of 26,423 shares. Based on an average trading volume of 4,116 shares, the days-to-cover ratio is presently 4.9 days. Currently, 0.1% of the company’s shares are short sold. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 4,116 shares, the days-to-cover ratio is presently 4.9 days.

Molecular Partners Price Performance

NASDAQ MOLN traded down $0.13 on Tuesday, reaching $4.30. The company had a trading volume of 4,297 shares, compared to its average volume of 4,163. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.91. The firm has a 50-day moving average of $4.16 and a 200-day moving average of $3.87. The firm has a market capitalization of $173.63 million, a PE ratio of -2.24 and a beta of 1.08.

Molecular Partners (NASDAQ:MOLN) last announced its earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05. As a group, sell-side analysts expect that Molecular Partners will post -1.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on MOLN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. JPMorgan Chase & Co. decreased their price target on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Molecular Partners presently has an average rating of “Hold” and a consensus target price of $7.88.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.